Key Takeaways
- De Novo means starting from zero. There is no predicate, so your cybersecurity baseline has to be defined and explained clearly
- Review decisions depend on how well things connect. Risks, controls, and testing should link together, not sit in separate sections
- Delays usually come from complicated documentation. Even good security work gets questioned if it is hard to follow
- Strong cybersecurity maturity helps move things faster. Clear risk handling, proper SBOM, and structured validation reduce back and forth
Introduction
Bringing a new medical device to market has never been simple. Today, more companies are choosing the De Novo pathway to introduce products that do not fit into existing classifications. This rise reflects innovation, but it also brings new pressure during the approval process.
At the same time, cybersecurity has moved from a background requirement to a key review factor. Many teams invest heavily in security controls, yet still face delays. The reason is often not the lack of protection, but how clearly it is explained and justified to the FDA.
If your submission does not tell a complete and traceable story, the review slows down.
In this guide, you will see how to approach cybersecurity in De Novo requests in a way that helps you move faster and avoid unnecessary back and forth.
What are De Novo Requests in FDA Submissions
If you are building something new, the usual FDA approval routes may not apply. That is where the De Novo pathway comes in. In simple terms, you use a De Novo request when your medical device has no legally marketed predicate device.
This means you cannot show similarity to an existing product. Instead, you are asking the FDA to create a new classification for your device based on its risk and intended use.
The De Novo request provides a marketing pathway to classify novel medical devices. It applies when general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but there is no legally marketed predicate device. De Novo classification is a risk-based classification process.
Once your device is approved through this route, it is placed into Class I or Class II. It can then serve as a predicate for future 510 k submissions, making it easier for similar devices to enter the market later.
The FDA has also formalized this process under the FD and C Act, giving companies a clear pathway to bring new types of devices to market as Class I or Class II products. You would typically choose the De Novo pathway when no substantially equivalent device exists or when your innovation introduces new risk profiles that cannot be compared directly.
How Cybersecurity Impacts the De Novo Approval Process
Cybersecurity is no longer treated as a supporting section in your submission. It now plays a central role in how the FDA reviews your device. This shift means reviewers examine your security approach as closely as safety and performance.
A key driver behind this change is Section 524B of the FD and C Act. It makes cybersecurity a required part of the submission process for software-enabled medical devices. Under this section, you must demonstrate reasonable assurance of cybersecurity.
This includes:
- A Software Bill of Materials
- A secure product development framework
- A plan for postmarket vulnerability monitoring
Regulators are actively strengthening the cybersecurity posture of the medical device ecosystem. As a result, your submission needs to show more than just implemented controls.
During the review, the FDA focuses on a few critical questions. Is security built into your system design from the beginning? Are risks clearly identified and properly controlled? Can you detect and manage vulnerabilities after the device is deployed?
How to Meet FDA Cybersecurity Requirements in De Novo Submissions
1. Establishing Security at the Design Level
The FDA is no longer satisfied with security added later in development. You need to show that you build cybersecurity into the design from the outset. This expectation comes directly from Section 524B, which requires you to show that your designed and maintain to ensure a reasonable level of cybersecurity.
This starts with how clearly you define your system. You should document your system architecture in a way that anyone reviewing it can understand how the device works, how components interact, and where risks may exist.
Focus on identifying the key elements of your system:
- Assets such as sensitive data, software components, and critical functions
- Entry points where an attacker could interact with the device
- Trust boundaries where data or control moves between different levels of security
2. Translating Risks into Controlled Design Decisions
A list of risks on its own does not explain much. What matters is how each one connects to what you actually built. Every risk should come from something specific in your system. It could be a communication interface, a data flow, or a software component. That context should lead directly to the control you chose.
FDA cybersecurity guidance follows a risk-based approach. The level of control and documentation should match the actual risk. To make this clear:
- Show where the risk comes from in your system
- Define the control used to reduce it
- Explain why that control is enough, including what risk still remains
Avoid broad labels that do not add clarity. Terms like “unauthorized access” without showing the path or condition behind it leave gaps in understanding. Threat modeling helps keep this grounded. It connects system behavior, possible attack paths, and mitigation choices in one flow, instead of spreading them across disconnected sections.
3. Proving Security Through Validation and Testing
Security design needs supporting evidence. That evidence comes from how the device performs when tested under real conditions. Testing should reflect actual use and misuse scenarios. It should show how the system behaves when exposed to inputs, interactions, and attack patterns that match real environments.
A complete approach usually includes:
- Penetration testing to simulate real-world attacks and observe how the device responds under active exploitation
- Static and dynamic analysis to examine code structure and runtime behavior
They also use additional methods like fuzz testing and vulnerability scanning to check how the system handles unexpected inputs and edge cases. The focus should stay on validation. Testing is not just about finding issues. It should confirm that the controls you implemented actually reduce the risks identified earlier.
4. Structuring SBOM and Dependency Visibility
Reviewers should be able to see exactly what your software contains without piecing things together. An SBOM is a complete inventory of all components in the device, including commercial, open source, and off-the-shelf software. It should follow the NTIA minimum elements and be provided in a machine-readable format.
Each component needs to clearly show:
- Version
- Dependencies, including transitive ones
- Known vulnerabilities such as CVEs
This is not just documentation. It helps track risk over time. When a new vulnerability appears, the SBOM makes it easier to identify affected components and take action quickly.
5. Demonstrating Postmarket Cybersecurity Readiness
Security does not stop once the device is approved. What happens after release carries equal weight, especially when new vulnerabilities keep appearing over time.
A clear postmarket approach shows how you identify, assess, and handle issues without delay. This includes continuous monitoring of vulnerabilities through internal systems, external databases, and coordinated disclosure channels.
Response timelines also matter. When a serious vulnerability is identified, communication is expected within 30 days. Followed by mitigation such as a patch within 60 days, depending on risk severity.
You need to plan patch delivery in a way that fits the device environment and does not disrupt its intended use. In many cases, you consider these update routine enhancements rather than major changes, as long as they reduce risk without introducing new issues.
Where Most De Novo Cybersecurity Submissions Break Down
Weak Threat Modeling
Many submissions mention threats, but they stay too generic. Risks are written at a high level without tying them to actual system behavior. When attack paths are not mapped to real interfaces or data flows, the analysis feels disconnected from the device itself.
Missing Traceability
Risk, control, and testing sections often exist, but they do not connect. One section lists risks, another lists controls, and testing sits somewhere else.FDA guidance clearly points to the need for traceability across these elements so that you can follow each risk through mitigation and validation.
Poor SBOM Structure
SBOMs are sometimes incomplete. That creates a visibility gap. Modern devices rely on many third-party components, each with its own risk profile. When vulnerabilities like Log4Shell appear, teams need to quickly check whether their devices are affected. Without a complete SBOM, that process slows down significantly.
Undefined Patching Process
Some submissions do not clearly explain how they will handle vulnerabilities after release. Missing timelines and unclear update methods raise concerns about how quickly they can resolve issues in real situations.
Overuse of Standards Without Application
Naming frameworks without showing where and how they are applied in the system or risk process does not add much value.
How Reviewers Evaluate Cybersecurity in De Novo Submissions
Reviewers are trying to understand your device quickly and confidently. If they have to interpret or guess what you meant, the review slows down. FDA guidance makes it clear that cybersecurity documentation should support an efficient review process and be structured in a way that is easy to follow.
De Novo requests process consulting services. Contact us to discuss your specific needs!
What They Look For
Clarity stands out more than volume. A well-structured submission makes it easier to see how everything fits together.
- Clear architecture diagrams that show system components and data flow
- A logical connection between risks, controls, and mitigation decisions
- Validation evidence that supports the controls implemented, not just test activity
These elements help reviewers quickly assess whether the device is designed and managed with cybersecurity in mind.
What Slows the Review Down
- Large documents with no clear organization
- Sections that do not connect with each other
- Missing justification for why a control or decision was made
When the submission feels scattered, reviewers spend more time trying to piece things together instead of evaluating the device itself.
5 Important Recommendations to Speed Up De Novo FDA Approval
1. Validate Your Approach Before Submission
Getting early feedback can save a lot of back and forth later. The Q Sub program lets you ask specific questions and discuss your approach before you submit. This helps align expectations early and reduces the chances of major changes during review.
2. Build Cybersecurity Into the Product, Not Around It
When security is added late, it usually leads to rework. Design changes, extra testing, and documentation updates start piling up. If security is part of the system from the beginning, everything stays consistent and easier to validate.
3. Focus on Traceability, Not Volume
Long documents do not help if nothing connects. What makes a difference is whether each risk links to a control, and each control links to verification. Simple tables often make this clearer than pages of explanation.
4. Structure Documents for Fast Review
A well-organized submission is easier to read and quicker to assess. Diagrams, tables, and clear cross-references help reviewers move through the content without stopping to interpret. FDA guidance also highlights the need for structured documentation to support efficient review.
5. Minimize Deficiency Cycles
Every deficiency adds time. Sometimes weeks, sometimes longer. Internal reviews, basic validation checks, and clear explanations go a long way in avoiding repeated questions during review.
Timelines: How Cybersecurity Impacts Approval Speed
- FDA review goal: ~150 review days
- Actual timeline: typically 6 to 12 months due to review holds and responses
Where time is lost: Deficiency cycles and Additional Information requests pause the review clock
Cybersecurity impact:
- Weak structure: +3 to 6 months
- Strong structure: fewer cycles, faster Approvals
How Qualysec Helps Streamline De Novo Cybersecurity
Qualysec works alongside your team to strengthen the parts of the submission that usually slow things down, especially around clarity and validation.
Their approach focuses on finding issues that actually matter. Instead of relying only on automated scans, they combine manual testing with automated methods to uncover deeper problems, including business logic flaws that standard assessments often miss.
This testing feeds directly into better documentation. They do not just list risks; they tie them to real attack scenarios, map them to controls, and support them with clear evidence.
That makes it easier to show how they identify, handle, and verify each issue.
In the De Novo submission, this brings three clear advantages:
- Stronger verification evidence through realistic penetration testing
- Clearer links between risks, controls, and validation results
- Well-structured, FDA-ready reports that are easier to review
The result is a submission that reads as a connected system, not a collection of separate documents.
Conclusion
In a De Novo requests submission, cybersecurity is not just another requirement to fill in. It shows how reviewers understand your entire system during review. When you clearly connect risks, controls, and validation, the submission becomes easier to evaluate and moves faster. When those connections are missing, even strong work gets stuck in cycles.
Teams that treat cybersecurity as part of design and documentation, rather than as an add-on, usually face fewer delays because they already align everything and make it easy to verify.
Are you ready to get clear, practical guidance for your De Novo submission with Qualysec experts
Speak directly with Qualysec’s certified professionals to identify vulnerabilities before attackers do.
FAQs
Q.What cybersecurity requirements apply to De Novo requests?
You need to submit proper cybersecurity documentation, not just a few notes. This includes a risk management report, system architecture, testing evidence, and an SBOM that lists all software components. These are now part of standard premarket expectations.
Q.How does cybersecurity affect De Novo request approval timelines?
If the cybersecurity section is clear and well-connected, the review moves faster. If it is confusing or incomplete, it leads to more questions and delays.
Q.What security testing is required for De Novo requests?
Testing should reflect real conditions. This usually includes penetration testing, code analysis, and checks that confirm your controls actually work, not just that they exist.
Q.What are common cybersecurity risks in De Novo requests?
Most risks arise from how you built and use the device. Common ones include exposed interfaces, weak authentication, insecure data handling, and risks from third-party software components.
Q.How can companies prepare cybersecurity documentation for De Novo requests?
Start with structure. Keep your architecture, risks, controls, and testing clearly connected. Your SBOM should be complete and up to date so you can track vulnerabilities over time, not just at submission.
0 Comments